http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-118407-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_093a9080c8f58422d6b85ce0a26a94d2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 |
| filingDate | 2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-118407-A1 |
| titleOfInvention | MULTIVALENT VACCINE COMPOSITION |
| abstract | This refers to a stable immunogenic combination vaccine or vaccines comprising a mixture of antigens for the prevention and prophylaxis of infections caused by rotavirus, polio virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and the Hepatitis B virus. The present provides in particular a multivalent combination vaccine comprising: i) IPV Salk or IPV Sabin (IPV) antigens in significantly reduced doses, prepared using improved formaldehyde inactivation and adsorption methods. aluminum hydroxide, resulting in maximum recovery of D antigen and ii) injectable heat-inactivated rotavirus antigen (s) derived from rotavirus strains (CDC-9) that provide broad cross-protective immunity between strains of human rotavirus, iii) Hib PRP-carrier protein conjugate having stability and immunogenicity improved quality wherein said PRP Hib-carrier protein conjugate is initially prepared using a new conjugation process and subsequently mixed at low temperature in the presence of a stabilizer to minimize the release of free PRP, iv) whole cell pertussis antigen with improved immunogenicity and stability obtained by adding whole cell pertussis antigen at a later stage in a mixture, thus minimizing degradation based on hydrolysis, v) homogeneous diphtheria toxoid and tetanus toxoid fractions obtained by removing unwanted aggregates by the use of gel permeation chromatography. Also described is the process to produce these stable immunogenic vaccine compositions by the steps of i) individually adsorbing IPV in reduced dose, IPV antigens on aluminum hydroxide, keeping the other antigen (s) unabsorbed or adsorbed on aluminum phosphate. , aluminum hydroxide, in a combination of aluminum hydroxide and aluminum phosphate and ii) using a particular order of antigen addition during mixing. |
| priorityDate | 2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.